As of Wednesday close, Acumen Pharmaceuticals Inc.’s (NASDAQ:ABOS) stock was up $0.05, moving up 0.79 percent to $6.36. The average number of shares traded per day over the past five days has been 100,280 shares. 2 times new highs have been achieved over the past 5 days, with a $0.21 gain in that time frame. In the last twenty days, the average volume was 148,015, while in the previous 50 days, it was 1,762,120.
Since last month, ABOS stock retreated -12.52%. Shares of the company fell to $5.66 on 11/14/22, the lowest level in the past month. A 52-week high of $10.97 was reached on 09/30/22 after having rallying from a 52-week low of $3.02. Since the beginning of this year, ABOS’s stock price has dropped by -5.92% or -$0.40, and marked a new high 4 times. However, the stock has declined by -42.02% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
In the three months ended June 29, Acumen Pharmaceuticals Inc.’s quick ratio stood at 30.60, while its current ratio was 30.60, showing that the company is able to pay off its debt. Based on annual data, ABOS earned $19.58 million in gross profit.
While analysts expected Acumen Pharmaceuticals Inc. to report -$0.24 quarterly earnings, the actual figure was -$0.25 per share, beating the consensus estimate by -4.20%. The liabilities of Acumen Pharmaceuticals Inc. were 6.61 million at the end of its most recent quarter ended June 29, and its total debt was $0.17 million. The value of shareholders’ equity is $40.92 million.
This quick technical analysis looks at Acumen Pharmaceuticals Inc.’s (ABOS) price momentum. With a historical volatility rate of 87.41%, the RSI 9-day stood at 45.47% on 23 November.
With respect to its five-day moving average, the current Acumen Pharmaceuticals Inc. price is up by +3.41% percent or $0.21. At present, ABOS shares trade -14.63% below its 20-day simple moving average and +33.89% percent above its 100-day simple moving average. However, the stock is currently trading approximately +7.61% above its SMA50 and +16.27% above its SMA200.
Stochastic coefficient K was 46.58% and Stochastic coefficient D was 42.16%, while ATR was 0.57. Given the Stochastic reading of 47.95% for the 14-day period, the RSI (14) reading has been calculated as 44.91%. As of today, the MACD Oscillator reading stands at -0.01, while the 14-day reading stands at -0.05.
BTIG Research launched its rating on Acumen Pharmaceuticals Inc. (NASDAQ: ABOS) to a Buy in a note to investors on July 15, 2022. Acumen Pharmaceuticals Inc. (ABOS) has been rated Buy by analysts. According to 0 brokerage firms, ABOS is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Acumen Pharmaceuticals Inc. stock as buy, with 5 recommending it as overweight.
With a median target price of $16.00, the current consensus forecast for the stock is $9.00 – $22.00. Based on these forecasts, analysts predict Acumen Pharmaceuticals Inc. (ABOS) will achieve an average price target of $15.60.